S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
Log in

NYSE:TAK - Takeda Pharmaceutical Stock Price, Forecast & News

$15.63
+0.18 (+1.17 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$15.34
Now: $15.63
$15.67
50-Day Range
$13.02
MA: $17.30
$20.31
52-Week Range
$12.43
Now: $15.63
$20.92
Volume1.43 million shs
Average Volume1.67 million shs
Market Capitalization$49.28 billion
P/E Ratio60.12
Dividend Yield3.88%
Beta0.92
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa. The company has a collaboration agreement with Lupus Therapeutics Inc. to evaluate the investigational biologic TAK-079 as a potential new therapy for Lupus in a Phase 1 trial. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Read More

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone813-3278-2306

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.88 billion
Cash Flow$2.22 per share
Book Value$29.75 per share

Profitability

Net Income$982.13 million

Miscellaneous

Employees49,578
Outstanding Shares3,152,748,000
Market Cap$49.28 billion
Next Earnings Date5/12/2020 (Estimated)
OptionableOptionable

Receive TAK News and Ratings via Email

Sign-up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter.


Takeda Pharmaceutical (NYSE:TAK) Frequently Asked Questions

How has Takeda Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

Takeda Pharmaceutical's stock was trading at $17.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TAK stock has decreased by 8.9% and is now trading at $15.63. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Takeda Pharmaceutical?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Takeda Pharmaceutical.

When is Takeda Pharmaceutical's next earnings date?

Takeda Pharmaceutical is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Takeda Pharmaceutical.

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Co Ltd (NYSE:TAK) released its quarterly earnings results on Tuesday, February, 4th. The company reported $0.53 earnings per share (EPS) for the quarter. The business earned $7.90 billion during the quarter. Takeda Pharmaceutical had a net margin of 2.25% and a return on equity of 13.17%. View Takeda Pharmaceutical's earnings history.

What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical issued an update on its FY 2019 Pre-Market earnings guidance on Tuesday, February, 4th. The company provided earnings per share (EPS) guidance of 3.53-3.72 for the period. The company issued revenue guidance of $30.147-30.147 billion.

What price target have analysts set for TAK?

4 equities research analysts have issued 12 month target prices for Takeda Pharmaceutical's shares. Their forecasts range from $19.50 to $30.00. On average, they expect Takeda Pharmaceutical's share price to reach $24.75 in the next year. This suggests a possible upside of 58.3% from the stock's current price. View analysts' price targets for Takeda Pharmaceutical.

Has Takeda Pharmaceutical been receiving favorable news coverage?

Media stories about TAK stock have trended very negative on Monday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Takeda Pharmaceutical earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutTakeda Pharmaceutical.

Who are some of Takeda Pharmaceutical's key competitors?

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Alibaba Group (BABA), Verizon Communications (VZ), Cisco Systems (CSCO), Walt Disney (DIS), Honeywell International (HON), Johnson & Johnson (JNJ), Home Depot (HD), AT&T (T), CVS Health (CVS) and NVIDIA (NVDA).

Who are Takeda Pharmaceutical's key executives?

Takeda Pharmaceutical's management team includes the following people:
  • Mr. Christophe Weber, Pres, CEO & Representative Director (Age 53)
  • Dr. Andrew S. Plump, Chief Medical & Scientific Officer and Director (Age 54)
  • Dr. Seigo Izumo M.D., Chair of Management Board
  • Mr. Costa Saroukos, Chief Financial Officer (Age 48)
  • Mr. Haruhiko Hirate, Member of Management Board & Corp. Communications and Public Affairs Officer (Age 62)

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Adelphi Capital LLP (0.29%), Macquarie Group Ltd. (0.16%), Macquarie Group Ltd. (0.16%), Bank of America Corp DE (0.13%), First Trust Advisors LP (0.07%) and Renaissance Technologies LLC (0.06%).

Which major investors are selling Takeda Pharmaceutical stock?

TAK stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, LMR Partners LLP, UBS Asset Management Americas Inc., TIG Advisors LLC, Janus Henderson Group PLC, Macquarie Group Ltd., Macquarie Group Ltd., and Franklin Resources Inc..

Which major investors are buying Takeda Pharmaceutical stock?

TAK stock was purchased by a variety of institutional investors in the last quarter, including Ovata Capital Management Ltd, Renaissance Technologies LLC, Raymond James & Associates, TD Asset Management Inc., Blueshift Asset Management LLC, Van ECK Associates Corp, Eagle Global Advisors LLC, and Magnetar Financial LLC.

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $15.63.

How big of a company is Takeda Pharmaceutical?

Takeda Pharmaceutical has a market capitalization of $49.28 billion and generates $18.88 billion in revenue each year. The company earns $982.13 million in net income (profit) each year or $0.51 on an earnings per share basis. Takeda Pharmaceutical employs 49,578 workers across the globe. View additional information about Takeda Pharmaceutical.

What is Takeda Pharmaceutical's official website?

The official website for Takeda Pharmaceutical is http://www.takeda.com/.

How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo M0, 103-8668. The company can be reached via phone at 813-3278-2306.


MarketBeat Community Rating for Takeda Pharmaceutical (NYSE TAK)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  87 (Vote Outperform)
Underperform Votes:  114 (Vote Underperform)
Total Votes:  201
MarketBeat's community ratings are surveys of what our community members think about Takeda Pharmaceutical and other stocks. Vote "Outperform" if you believe TAK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TAK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Featured Article: Inflation

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel